aGvHD	acute Graft-versus-Host Disease
allo-HCT	allogeneic hematopoietic stem cell transplantation
ALL	acute lymphocytic leukemia
AML	acute myeloid leukemia
CAIX	carbonic anhydrase IX
CAR	chimeric antigen receptor
CD	cluster of differentiation
cGvHD	chronic Graft-versus-Host Disease
CI	checkpoint inhibition/inhibitor
CR	complete remission
CRS	cytokine release syndrome
CRISPR/Cas9	clustered regularly interspaced short palindromic repeats associated with Cas9 endonuclease
CTLA-4	cytotoxic T-lymphocyte-associated protein-4
DLBCL	diffuse large B-cell lymphoma
DLI	donor lymphocyte infusion
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
FDA	Food and Drug Administration
FL	follicular lymphoma
FOXP3 GD2	Forkhead-box-protein P3 disialoganglioside
GvHD	Graft-versus-Host Disease
GvL	Graft-versus-leukemia
GvT	Graft-versus-tumor
HD	Hodgkin’s disease
(c)HL	(classical) Hodgkin lymphoma
ICANS	immune cell associated neurotoxicity syndrome
ICOS	inducible T cell costimulator
irAEs	immune-related adverse events
KLRG-1	killer cell lectin-like receptor subfamily member 1
LAG-3	lymphocyte-activation gene 3
mAbs	monoclonal antibody
MDS	myelodysplastic syndrome
MGMT	0-6-Methylguanine DNA-methyltransferase
MiHA	minor histocompatibility antigen
MF	myelofibrosis
NHL	Non-Hodgkin-Lymphoma
ORR	overall response rate
OS	overall survival
PD-1	programmed death-1
PD-L1	programmed death- ligand 1
PFS	progression free survival
PMBCL	primary mediastinal B cell lymphoma
PR	partial remission
RNA	ribonucleotide acid
scFv	single chain variable fragment
SD	stable disease
TIGIT	T cell immunoglobulin and ITIM domains
TIM-3	T-cell immunoglobulin mucin-3